Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 18.
doi: 10.1016/j.psym.2020.05.006. Online ahead of print.

Psychopharmacology of COVID-19

Free PMC article

Psychopharmacology of COVID-19

Melanie Bilbul et al. Psychosomatics. .
Free PMC article


Background: With the rapid, global spread of SARS-CoV-2, hospitals have become inundated with patients suffering from COVID-19. Consultation-liaison psychiatrists are actively involved in managing these patients and should familiarize themselves with how the virus and its proposed treatments can affect psychotropic management. The only FDA approved drug to treat COVID-19 is remdesivir, and other off-label medications used include chloroquine and hydroxychloroquine, tocilizumab, lopinavir/ritonavir, favipiravir, convalescent plasma therapy, azithromycin, vitamin C, corticosteroids, interferon and colchicine.

Purpose: To provide an overview of the major safety considerations relevant to clinicians who prescribe psychotropics to patients with COVID-19, both related to the illness and its proposed treatments.

Methods: In this targeted review we performed structured literature searches in PubMed to identify articles describing the impacts of COVID-19 on different organ systems, the neuropsychiatric adverse effects of treatments, and any potential drug interactions with psychotropics. The articles most relevant to this manuscript were included.

Results: COVID-19 impacts multiple organ systems, including gastrointestinal, renal, cardiovascular, pulmonary, immunological, and hematological systems. This may lead to pharmacokinetic changes that impact psychotropic medications and increase sensitivity to psychotropic-related adverse effects. Additionally, several proposed treatments for COVID-19 have neuropsychiatric effects and potential interactions with commonly used psychotropics.

Conclusion: Clinicians should be aware of the need to adjust existing psychotropics or avoid using certain medications in some COVID-19 patients. They should also be familiar with neuropsychiatric effects of medications being used to treat this disease. Further research is needed to identify strategies to manage psychiatric issues in this population.

Keywords: COVID-19; psychopharmacology; psychotropic; side effects.

Similar articles

See all similar articles


    1. Fact Sheet for Healthcare Providers - Emergency Use Authorization (EUA) of Remdesivir (GS-5734TM) [Internet]. U.S. Food and Drug Administration (FDA). 2020. Available from:
    1. Kalil AC. Treating COVID-19—Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA [Internet]. 2020 Mar 24; Available from: 10.1001/jama.2020.4742 - DOI
    1. Wang T., Du Z., Zhu F., Cao Z., An Y., Gao Y. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet [Internet] 2020 Mar 21;395(10228):e52. doi: 10.1016/S0140-6736(20)30558-4. Available from: - DOI
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet] 2020;395(10223):497–506. Available from:
    1. Terpos E., Ntanasis-Stathopoulos I., Elalamy I., Kastritis E., Sergentanis T.N., Politou M. Hematological findings and complications of COVID-19. Am J Hematol [Internet] 2020 Apr 13 doi: 10.1002/ajh.25829. n/a(n/a). Available from: - DOI